Modality
ERT
MOA
BiTE
Target
C5
Pathway
STING
ADHDHCC
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
May 2019
→ Oct 2029
Phase 2Current
NCT06005824
41 pts·HCC
2019-05→2029-10·Terminated
NCT06507517
2,742 pts·ADHD
2021-02→2026-08·Completed
2,783 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-255mo awayPh2 Data· ADHD
2029-10-113.5y awayPh2 Data· HCC
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Termina…
P2
Complet…
Catalysts
Ph2 Data
2026-08-25 · 5mo away
ADHD
Ph2 Data
2029-10-11 · 3.5y away
HCC
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06005824 | Phase 2 | HCC | Terminated | 41 | PANSS |
| NCT06507517 | Phase 2 | ADHD | Completed | 2742 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| ARG-1250 | Argenx | Phase 2 | C5 |